Transcript
**0:00** · Hello everybody. So Hims has a huge news today. Hims is finally selling Lily's full lineup of GLP1s.**0:16** · This is a news we've been waiting for, at least for me, probably close to two years, a year and a half. Uh it was always a problem that Himps didn't sell Lily's products because if Himps doesn't have the full set of options, why would you go on HIM's website? Of course, the big underlying reason I believe why HIMS couldn't have Lily's products is because while Life MD and Row had them, may I remind everyone that Rorow is five times smaller than HIMS. Life MD is probably what 10 times smaller than HIMS. Okay, HIMS is the big kahuna. It's the big player in the market. It's nearly half of Tellah Health. The fact that this today happened is absolutely amazing news. Now HIMS becomes a neutral ground, a neutral distribution ground for drug companies to compete. It's back in the 70s, back in the early days, if a grocery store didn't have Coca-Cola, you wouldn't drive to that grocery store because you wanted to have Coca-Cola as your option. Coke. You wanted to have it as your option. Option Coca-Cola. This is the same. A lot of people were not going to go to the HIMS platform if they knew that HIMS couldn't prescribe them one of the type of GLP1s.**1:41** · This is such a huge news. This is even more of a huge news that people who are going to usually look for tier zepide are going to be less healthy people because tier zepide is the is is the the highest action the most effective GLP1.**1:59** · Now it's on hims. So himach is going to have an inflow of less healthy people to which they can cross-ell cross-ell maybe anxiety cross-ell maybe ED maybe air loss it's all related they can this is this is an enormous news right this is this is such an enormous news and I when I said a few a few weeks ago I made a video that saying they've turned the market into a casino I'm very serious they've turned the market into a casino look at look at what's happening with car Avis today. They've turned the market into a casino. The fact that the biggest news in two years for him would lead to the stock being down 1.4%.**2:44** · And the fact by the way that when the business was much riskier with no no teet no with legal risk legal overhang compounded GLP ones the stock was trading at 60 last year with all of these risks now the risks are are are mostly gone I don't see the risk anymore where's the risk there they they sell the branded stuff now and the stock is down 2%. This is this is unfathomable unfathomable this price action. Yes, investing.com their article is correct.**3:25** · Sturge is 7%. It should it should have served 30%.**3:30** · Not 7%. On this and we get a 1.4% down.**3:36** · This is the biggest news in nearly two years. Lily's GLP-1 is the top GLP-1.**3:43** · It's tiered zipper tide. It's dual action.**3:47** · It it it makes you lose weight faster than Novo. No offense to Novo. Novo is a great product, but Novo is for slightly less overweight people, right? This this tears appetite is the blockbuster. And now HIMS has it. So, so anyways, the amount of bears who who have come on X, by the way, this morning, I can I cannot believe the amount of bear with with no argument, just personal attacks, no argument, right? Calling people who love him, calling them baby analysts or or or dumb because they don't follow Wall Street. Excuse me. Of course. Of course.**4:29** · I'm going to have no respect for Wall Street and absolutely zero respect for like 90% of analysts when you see this madness. Analysts just keep moving the price target on HIMS depending on where HIMS moves. They keep they keep saying neutral and they move it where it moves.**4:46** · They don't analyze HIMS. HIMS is too different of a company. It's too too tech. It's too zero to one. It is too Netflix-l like or Spotify like it's too too much like that for them to understand. Wall Street has missed 0ero to1 stories over and over and over again. Anyways, I had a joke here, little idea for the merch store. Maybe maybe the Bears and there's so many of them. Maybe they would buy a Hims punching bag because this is what him stock has been for the past two years.**5:26** · So, so, so merch idea. You probably would have a lot of bears buying a HIMS punching bag. I like that idea a lot.**5:36** · Make money on the bears because this is literally what this stock has been. So, anyways, let's get into the details.**5:43** · What are the details? Well, first of all, typical big tech agile 0ero to1 company. It's already on the website.**5:51** · It's already first page on the website.**5:54** · Funio is at him. Zebound the quick pen is at him. Tzippetide and funio of course is is tier zipide in a pill with with their own system slightly different but you get what I mean. Um, and people are people are getting um concerned that HIMS didn't call it a partnership in the press release. Uh, well, they didn't call it a partnership because they're sending the prescription to Lily Direct.**6:21** · So, HIMS essentially acts as an API, but to me to to me to me that makes absolutely no difference to I mean, I call it a partnership. To me, it's the same as a partnership. Why do why do I say it's the same as a partnership? To me, because they received permission.**6:35** · They received the go-ahad from Lily.**6:38** · Lily probably said, "Yeah, okay. We can supply it now." Like the supply is here.**6:43** · We don't have supply chain issues. We now think that we can supply the extreme demand that you hims can provide to us.**6:51** · There was some messaging going on in there. So, it's not a partnership per se because Lily probably makes most if not all of the money. From what I understand, they're probably going to make all of the money on on actually selling the drug. But guess what? This is not a problem at all because HIMS is making the full membership fee 149. The full membership fee is going to HIMS and and okay, HIMS is is full of AI powered nurse practitioners. AI powered nurse practitioners. Yes, there are MDs on the HIMS platform. Last time I checked, they they had reported having I think 1,500 providers, but the Mnes are not the bulk of these providers. Like a lot of these providers, if not I don't want to say most because I don't know, but a lot of these providers are NPs. NPs are much much much cheaper and they're AI enabled NPs. So that that 149 fee to me monthly fee to me that's going to be mostly margin. And that's why they can offer the first month, by the way, at 39 bucks for a first month. To me, that's that's going to be mo mostly margin. I don't know what the margin is going to be, but maybe 90%. Right? Maybe 80% to make it in line with the rest of the business, maybe higher if you have an easy case, maybe worse if you have if you have an uneasy case, but but that partnership fee is going to is going to be very very high margin, you know, SAS tech like margins, and it's all theirs to keep. So, so, so I I'm very impressed by this partnership. We were expecting it. And going over, of course, the early Netflix days analogy. I love that Dudom roots his analogies in big tech, right?**8:42** · Doesn't follow Wall Street. The the model is not United Healthcare. The model is Netflix. The model is Spotify.**8:51** · That's that's the model. And of course in the early days of Netflix, Netflix depended on having blockbusters in its catalog. Even if you remember Netflix back in I think it was 2014 2015 um you know HBO you know TR media didn't see Netflix as a threat. So they were like sure uh give us 100 million bucks and we'll give you Game of Thrones, we'll give you Big Bang Theory. So Netflix in the early days gained a lot of customers because they had all of the top shows distributed on the Netflix streaming platform and if you didn't have those top shows why would anybody pay 15 bucks a month if you don't have the hottest show which back then was was Game of Thrones right and so back then Netflix had the hottest show and people registered to Netflix because Netflix had the hottest show now has the hottest GLP one which And he is going to have the hottest product in pharma's entire history which is going to be retatride and if they have a Lily partnership they will have retatride and so I I I cannot even fathom how big this news is because retatride is going to be the ultimate game changer. It will be approved by the FDA probably second half of the year. And when it's approved, does that mean Hims is going to have it? Most likely because now HIMS sells the full lineup of Novo of Novo, sorry, of Lily. So that's going to be an enormous enormous enormous deal. And yes, I do think the HIMS vision, and it's a blurry vision, but the vision of of HIMS is a vertically integrated new kind of health company down the road.**10:40** · And we know they have of course this this peptide manufacturing facility.**10:44** · They have this compounding manufacturing facility. They've hired uh generics uh a generic executive I think on their board or something like that. I off the top of my head I don't I don't remember but um yeah eventually eventually I believe he will make its own its own drugs. So maybe it will not use uh the raw ingredients or the raw material. But if you if you move to fully AI designed and AI customized compounded drugs, HIMS will will very very much look like a vertically integrated company who brings a lot of stuff inhouse and does a lot of stuff inhouse just like Netflix does. Netflix makes a lot of its own shows now and they have their own style which I don't like by the way. I don't really like Netflix shows, but that's that's that's beyond the point, you know. Will will will Spotify make its own music with AI at some point? Well, it's it's already becoming more and more of the case, but I I I believe at some point Spotify will make the music, right? Netflix makes the shows. Hims at some point will make the drugs and and these industries will consolidate. And and and to me, HIMS is big tech. Hims is going to be big tech.**11:54** · Most people don't see it yet.**11:56** · And lastly, let me conclude, of course, with the cross-selling. I already said that, but the cross-selling is going to just be huge because the people who go on tier zepide are typically more in need of medical um uh help and and because they're typically bigger, cross-selling is going to be huge.**12:17** · Imagine that. You have someone who comes to him and they want they they want to get zip bound and then maybe hims, you know, every other day you send a push notification on the phone. Hey, do you have EG problems? And then you start selling hard mints or something like that. Easy. You got you got their info, you got their credit card, you got their relationship, you can crossell. This is this is an enormous news for him. And the fact that the stock is down really, really, really tells me fundamental analysis needs to make a comeback. I am so tired of Wall Street manipulating these stocks. That's what Wall Street is doing. It's it's it's manipulation.**13:01** · Anyways, this was not investment advice.**13:04** · This is not financial advice. This is only entertainment. I'm hoping you are entertained. Please like, please subscribe. Follow me on Patreon. Follow me on X. Thank you for watching and have a wonderful, wonderful day.